Need professional-grade analysis? Visit stockanalysis.com
$18.92M
N/A
10
N/A
XTL Biopharmaceuticals Ltd (XTLB) trades on TA in ILS. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at ILS1.90.
Over the past year, XTLB has traded between a low of ILS1.90 and a high of ILS8.70. The stock has lost 61.2% over this period. It is currently 78.2% below its 52-week high.
XTL Biopharmaceuticals Ltd has a market capitalization of $18.92M.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Side-by-side comparison against top Healthcare peers.